Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human PAK4 Antibodies:
anti-Mouse (Murine) PAK4 Antibodies:
anti-Rat (Rattus) PAK4 Antibodies:
Go to our pre-filtered search.
Human Polyclonal PAK4 Primary Antibody for EIA, IHC (p) - ABIN360324
Lu, Pan, Devaux, Ray: p21-activated protein kinase 4 (PAK4) interacts with the keratinocyte growth factor receptor and participates in keratinocyte growth factor-mediated inhibition of oxidant-induced cell death. in The Journal of biological chemistry 2003
Show all 2 references for ABIN360324
Human Monoclonal PAK4 Primary Antibody for WB - ABIN967342
Abo, Qu, Cammarano, Dan, Fritsch, Baud, Belisle, Minden: PAK4, a novel effector for Cdc42Hs, is implicated in the reorganization of the actin cytoskeleton and in the formation of filopodia. in The EMBO journal 1999
Show all 2 references for ABIN967342
Rat (Rattus) Polyclonal PAK4 Primary Antibody for WB - ABIN610860
Jones, Jakubowicz, Pitossi, Maurer, Hemmings: Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily. in Proceedings of the National Academy of Sciences of the United States of America 1991
Show all 2 references for ABIN610860
Human Polyclonal PAK4 Primary Antibody for ELISA, IF - ABIN4343475
Liu, Yang, Liu, Liu, Zhang, Xu, Zhu, Xu: p21-Activated kinase 4 predicts early recurrence and poor survival in patients with nonmetastatic clear cell renal cell carcinoma. in Urologic oncology 2015
High expression of PAK4 is associated with breast cancer.
In gastric cancer, High PAK4 expression was significantly correlated with clinicopathological variables related to tumour progression, including depth of invasion, metastatic lymph nodes, pathological stage, distant metastasis or recurrent disease. High PAK4 expression was significantly associated with poorer disease-specific survival and relapse-free survival.
PAK4 methylation by SETD6 (show SETD6 Antibodies) promotes the activation of the Wnt (show WNT2 Antibodies)/beta-catenin (show CTNNB1 Antibodies) pathway.
Study has confirms prognostic role of PAK4 level in cervical cancer patients and recognizes the regulatory role in cervical cancer progression. PAK4 also confers the chemoresistance of cervical cancer cells in a PI3K (show PIK3CA Antibodies)/Akt (show AKT1 Antibodies)-dependent way.
PAK4 catalytic domain binds cellular ATP and the Inka1 inhibitor. The crystal lattice consists only of PAK4-PAK4 contacts, which form a hexagonal array with channels of 80 A in diameter that run the length of the crystal.
PAK4 localizes to cell-cell junctions and contributes to estblishing cell polarity.PAK4 phosphorylate beta-catenin (show CTNNB1 Antibodies) Serine-675.PAK4 binding to cell-cell junctions is dependent on Cdc42 (show CDC42 Antibodies).
Nuclear Pak4 is involved in the pathogenesis of endometrial cancer especially in postmenopausal women.
data show decreased nuclear accumulation and transcriptional activity of STAT3 (show STAT3 Antibodies) in PAK4-silenced pancreatic cancer cells
this report reveals that high level of p-Pak4 correlates with poor prognosis in gastric cancer (GC), thereby suggesting that p-Pak4 might be a potential prognostic marker for GC.
PAK4 and RhoU (show RHOU Antibodies) cooperate to drive adhesion turnover and promote cell migration.
PAK4 microparticles may have a role in the ventilation-induced lung injury process
These data demonstrate the relevance of PAK4 in osteoclast differentiation and the potential of PAK4 inhibitors for treating osteoclast-related disorders.
PAK4 promotes alpha-MSH/UVB-induced melanogenesis via the CREB (show CREB1 Antibodies) and Wnt (show WNT2 Antibodies)/beta-catenin (show CTNNB1 Antibodies) signaling pathways and suggest that PAK4 may be a potential therapeutic target in pigmentation disorders.
PAK4 phosphorylates Par6B (show PARD6B Antibodies) at Ser143 blocking its interaction with Cdc42 (show CDC42 Antibodies).
Defined here is the overlap in phosphopeptides regulated by K-Ras (show HRAS Antibodies), Cdc42 (show CDC42 Antibodies), and PAK4; perturbation of these signaling components affects phosphoproteins associated with microtubule depolymerization, cytoskeletal organization, and the cell cycle.
These results indicate that PAK4 functions, including control of actin dynamics, are necessary for normal development of the heart
p21-activated kinase 4 regulates regulatory myosin light chain phosphorylation and myosin contractility during FcgammaR-mediated phagocytosis.
the transient increase in PAK4 levels at early G1 reduces p21 (show D4S234E Antibodies) levels, thereby abrogating the activity of CDK4 (show CDK4 Antibodies)/CDK6 (show CDK6 Antibodies) kinases, and allowing cells to proceed with the cell cycle in a precisely coordinated way
Conditional Pak4 knockout mice were born normally, but displayed growth retardation and died prematurely. The brains showed a dramatic decrease in proliferation of cortical and striatal neuronal progenitor cells.
results suggest that overexpression of Pak4 triggers events that are important for the transformation of mammary epithelial cells
PAK proteins, a family of serine/threonine p21-activating kinases, include PAK1, PAK2, PAK3 and PAK4. PAK proteins are critical effectors that link Rho GTPases to cytoskeleton reorganization and nuclear signaling. They serve as targets for the small GTP binding proteins Cdc42 and Rac and have been implicated in a wide range of biological activities. PAK4 interacts specifically with the GTP-bound form of Cdc42Hs and weakly activates the JNK family of MAP kinases. PAK4 is a mediator of filopodia formation and may play a role in the reorganization of the actin cytoskeleton. Multiple alternatively spliced transcript variants encoding distinct isoforms have been found for this gene.
p21-activated kinase 4
, p21(CDKN1A)-activated kinase 4
, protein kinase related to S. cerevisiae STE20, effector for Cdc42Hs
, serine/threonine-protein kinase PAK 4
, p21 (CDKN1A)-activated kinase 4